MN HF2541

Allows sale of products containing cannabinoids extracted from hemp for human or animal consumption, excluding products sold by registered medical cannabis manufacturers.

Requires independent, accredited third-party laboratory testing to verify cannabidiol content matches label claims, confirm absence of excessive pesticides/fertilizers/heavy metals, and ensure tetrahydrocannabinol does not exceed industrial hemp limits.

Mandates product labels include manufacturer contact information, testing laboratory name and address, accurate cannabidiol amount or percentage per unit, and FDA disclaimer unless product has been FDA-approved.

Classifies products as adulterated drugs if they contain filthy or decomposed substances, are produced under unsanitary conditions, have poisonous containers, contain unsafe color additives, or contain cannabidiol amounts differing from label statements.

Classifies products as misbranded drugs if labeling is false or misleading, required information is not prominently displayed, or labels make disease prevention or treatment claims without FDA approval; prohibits sellers from making false health benefit claims.

Grants Board of Pharmacy authority to issue cease and desist orders, embargo misbranded and adulterated drugs, and seek injunctive relief for violations.